Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology).
Inal A, Kodaz H, Odabas H, Duran AO, Seker MM, İnanc M, Elkıran ET, Gunaydın Y, Menekse S, Topcu TO, Urakcı Z, Tastekin D, Bilici M, Cihan S, Geredeli C, Sezer E, Uncu D, Arpacı E, Ozturk B, Bal O, Uysal M, Tanrıverdi O, Gumus M, Oven Ustaalioglu BB, Suner A, Cokmert S, Hacıbekiroglu İ, Aydın K, Isıkdogan A. Inal A, et al. Among authors: geredeli c. J Cancer Res Ther. 2018 Apr-Jun;14(3):578-582. doi: 10.4103/0973-1482.176417. J Cancer Res Ther. 2018. PMID: 29893321 Free article.
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Karacin C, et al. Among authors: geredeli c. BMC Cancer. 2023 Feb 10;23(1):136. doi: 10.1186/s12885-023-10609-8. BMC Cancer. 2023. PMID: 36765293 Free PMC article.
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
Göksu SS, Tatlı AM, Geredeli Ç, Atcı M, Besen AA, Mertsoylu H, Uysal M, Özdoğan M, Aydın SG, Bilici A, Karaağaç M, Artaç M, Kaplan MA, Ebinç S, Coşkun HŞ. Göksu SS, et al. Among authors: geredeli c. Cancer Chemother Pharmacol. 2021 Nov;88(5):805-812. doi: 10.1007/s00280-021-04328-9. Epub 2021 Jul 26. Cancer Chemother Pharmacol. 2021. PMID: 34312705
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Karacin C, et al. Among authors: geredeli c. BMC Cancer. 2023 Feb 27;23(1):192. doi: 10.1186/s12885-023-10662-3. BMC Cancer. 2023. PMID: 36849943 Free PMC article. No abstract available.
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Uğraklı M, Koçak MZ, Dinç G, Genç TB, Çağlayan M, Uğraklı S, Hendem E, Er MM, Çağlayan D, Eryılmaz MK, Araz M, Geredeli Ç, Tatlı AM, Eren OÖ, Artaç M. Uğraklı M, et al. Among authors: geredeli c. J Cancer Res Clin Oncol. 2023 Sep;149(11):9183-9189. doi: 10.1007/s00432-023-04844-6. Epub 2023 May 15. J Cancer Res Clin Oncol. 2023. PMID: 37184681
Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology).
İnal A, Kos FT, Algın E, Yıldız R, Berk V, Unek İT, Colak D, Dane F, Geredeli C, Isıkdogan A. İnal A, et al. Among authors: geredeli c. Contemp Oncol (Pozn). 2015;19(2):125-9. doi: 10.5114/wo.2014.43933. Epub 2015 May 13. Contemp Oncol (Pozn). 2015. PMID: 26034390 Free PMC article.
57 results